Search for publications

Search results

4733 items matching your search terms.

Reacting to prognostic covariate imbalance in randomised controlled trials

Coskinas, X. Schou, I. M. Simes, J. Martin, A.
CONTEMPORARY CLINICAL TRIALS, 2021     DOI:10.1016/j.cct.2021.106544

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort

Daniels, B. Kiely, B. E. Tang, M. Houssami, N. Lord, S. J. Pearson, S. A.
BREAST, 2021     DOI:10.1016/j.breast.2021.05.001

The IDEAL trial in Australia and New Zealand: Clinical and Economic impact

Dansie, K. B. Davies, C. E. Morton, R. L. Hawley, C. M. Johnson, D. W. Craig, J. C. Chapman, J. R. Cooper, B. A. Pollock, C. A. Harris, D. C. H. McDonald, S. P.

A survey of obstetricians' attitudes to induction of labour at 39 weeks gestation with the intention of reducing caesarean section rates

Davis, G. Waldman, B. Phipps, H. Hyett, J. de Vries, B.

A meta-review demonstrates improved reporting quality of qualitative reviews following the publication of COREQ- and ENTREQ-checklists, regardless of modest uptake

de Jong, Y. van der Willik, E. M. Milders, J. Voorend, C. G. N. Morton, R. L. Dekker, F. W. Meuleman, Y. van Diepen, M.
BMC MEDICAL RESEARCH METHODOLOGY, 2021     DOI:10.1186/s12874-021-01363-1

Person centred care provision and care planning in chronic kidney disease: which outcomes matter? A systematic review and thematic synthesis of qualitative studies : Care planning in CKD: which outcomes matter?

de Jong, Y. van der Willik, E. M. Milders, J. Meuleman, Y. Morton, R. L. Dekker, F. W. van Diepen, M.
BMC NEPHROLOGY, 2021     DOI:10.1186/s12882-021-02489-6

Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: Secondary analysis from the FOURIER randomized clinical trial

Deedwania, P. Murphy, S. A. Scheen, A. Badariene, J. Pineda, A. L. Honarpour, N. Keech, A. C. Sever, P. S. Pedersen, T. R. Sabatine, M. S. Giugliano, R. P.
JAMA CARDIOL, 2021     DOI:10.1001/jamacardio.2020.3151

A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial

Dennis, M. Burnett, A. Hills, R. Thomas, I. Ariti, C. Severinsen, M. T. Hemmaway, C. Greaves, P. Clark, R. E. Copland, M. Russell, N. National Cancer Research Institute acute myeloid leukaemia Working, Group
BRITISH JOURNAL OF HAEMATOLOGY, 2021     DOI:10.1111/bjh.17501

Efficacy of a combination of conservative therapies vs an education comparator on clinical outcomes in thumb base osteoarthritis: A randomized clinical trial

Deveza, L. A. Robbins, S. R. Duong, V. Bennell, K. L. Vicenzino, B. Hodges, P. W. Wajon, A. Jongs, R. Riordan, E. A. Fu, K. Oo, W. M. O'Connell, R. L. Eyles, J. P. Hunter, D. J.
JAMA INTERN MED, 2021     DOI:10.1001/jamainternmed.2020.7101

ASO Author Reflections: Longitudinal diagnostic accuracy of surveillance imaging in resected stage iii melanoma patients

Dieng, M. Morton, R. L.
ANNALS OF SURGICAL ONCOLOGY, 2021     DOI:10.1245/s10434-020-09407-4

Reply to: CT and PET/CT surveillance in Stage IIIA-D melanoma results in more false-positive than true-positive findings and should not be routinely recommended, by Nicholas Taylor et al

Dieng, M. Lord, S. J. Nieweg, O. E. Saw, R. P. M. Einstein, A. J. Nijhuis, A. A. G. Turner, R. M. Thompson, J. F. Morton, R. L.
ANNALS OF SURGICAL ONCOLOGY, 2021     DOI:10.1245/s10434-021-09821-2

Personalizing first-line systemic therapy in metastatic colorectal cancer: is there a role for initial low-intensity therapy in 2021 and beyond? a perspective from members of the Australasian Gastrointestinal Trials Group

Dunn, C. Hong, W. Gibbs, P. Ackland, S. Sjoquist, K. Tebbutt, N. C. Price, T. Burge, M.
CLINICAL COLORECTAL CANCER, 2021     DOI:10.1016/j.clcc.2021.05.001

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

Edmondson, R. J. O'Connell, R. L. Banerjee, S. Mileshkin, L. Sykes, P. Beale, P. Fisher, A. Bonaventura, A. Millan, D. Nottley, S. Benson, C. Hamilton, A. Sjoquist, K. Alexander, L. Kelly, C. Carty, K. Divers, L. Bradshaw, N. Friedlander, M. Paragon investigators
GYNECOLOGIC ONCOLOGY, 2021     DOI:10.1016/j.ygyno.2021.09.010

ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Emmett, L. Subramaniam, S. Joshua, A. Crumbaker, M. Martin, A. Zhang, A. Y. Rana, N. Langford, A. Mitchell, J. Yip, S. Francis, R. Hofman, M. S. Sandhu, S. Azad, A. Gedye, C. McJannett, M. Stockler, M. R. Davis, I. D. Australian, New Zealand, Urogenital Prostate Cancer Trials, Group the, Enza-p investigators
BJU INTERNATIONAL, 2021     DOI:10.1111/bju.15491

Gaps in care and support for patients with advanced breast cancer: A report from the Advanced Breast Cancer Global Alliance

Fallowfield, L. Boyle, F. M. Travado, L. Kiely, B. E. Jewell, P. Aubel, D. Cardoso, F.
JCO GLOB ONCOL, 2021     DOI:10.1200/GO.21.00045